| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9236153 | Best Practice & Research Clinical Gastroenterology | 2005 | 9 Pages |
Abstract
Researchers interested in developing treatments for hepatocellular carcinoma (HCC) face three sets of problems; one set common to all clinical trialists at the beginning of the 21st century, one set related to phase I/II studies ('early drug development') and one set related to the design of phase III (randomised, controlled trials). This review is concerned with the challenges faced in designing high quality clinical trials in patients with HCC. Specific published trials are not discussed other than by way of illustration of the problems faced.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Philip J. (Professor of Oncology and Translational Research, Director of the Clinical Trials Unit), Lucinda J. (Senior Biostatistician),